Related Experiment Video
Updated: Jan 9, 2026

Macrophage Differentiation and Polarization into an M2-Like Phenotype using a Human Monocyte-Like THP-1 Leukemia Cell Line
Published on: August 2, 2021
SPHK1-mediated M2 macrophage polarization drives TGF-β1-dependent thrombus fibrosis
Xiaoyun Chen1, Fajiu Li2, Guofeng Ma3
1The School of Clinical Medicine, Fujian Medical University, Department of Respiratory and Critical Care Medicine, Fujian Provincial Geriatric Hospital, Fuzhou, China.
Background And Objective:
Venous thrombus fibrosis contributes to post-thrombotic syndrome (PTS) and chronic thromboembolic pulmonary hypertension (CTEPH). M2 macrophages promote fibrosis via TGF-β1 secretion. This study investigates whether sphingosine kinase 1 (SPHK1) promotes thrombus fibrosis by regulating M2 macrophage polarization.
Methods:
Histological staining and immunofluorescence (IF) were performed on thrombus tissues from patients with acute thrombosis and CTEPH. Single-cell RNA sequencing (scRNA-seq) was used to characterize immune cell heterogeneity and to identify SPHK1 expression within macrophage subsets. In vivo, a rat model of thrombus was established via inferior vena cava (IVC) ligation, and the SPHK1 inhibitor PF543 was administered to evaluate its effects on fibrosis and macrophage polarization. In vitro, bone marrow-derived macrophages (BMDMs) were subjected to M2 polarization and co-cultured with fibroblasts to assess the TGF-β1-dependent fibroblast activation.
Results:
Histological analysis revealed significantly increased ECM deposition and macrophage infiltration in CTEPH thrombi compared to acute thrombi. Masson staining demonstrated extensive collagen fiber accumulation in CTEPH samples. Immunofluorescence analysis of fibrotic thrombi from a rat inferior vena cava (IVC) ligation model showed strong co-expression of SPHK1 and CD68, indicating the presence of SPHK1-expressing macrophages in thrombus remodeling. scRNA-seq analysis further revealed high SPHK1 expression in M2 macrophage subsets, particularly in the MARCO-1 cluster, and its expression was closely correlated with TGF-β1 secretion. In vivo, PF543 treatment significantly reduced collagen deposition, TGF-β1 expression, and M2 macrophage polarization in thrombus tissue. In vitro, SPHK1 knockdown markedly suppressed the expression of TGF-β1, Arg1, CD36, and FASN in BMDMs, indicating an inhibition of pro-fibrotic macrophage function. Co-culture experiments further confirmed that M2 macrophages activated fibroblasts via a TGF-β1-dependent mechanism.
Conclusion:
This study demonstrates that SPHK1 promotes M2 macrophage polarization and drives TGF-β1-dependent thrombus fibrosis, underscoring its critical role in the progression of CTEPH. Pharmacological inhibition of SPHK1 by PF543 effectively attenuates fibrotic remodeling and suppresses M2 macrophage polarization, suggesting that SPHK1 may serve as a promising therapeutic target for the treatment of chronic thrombus-associated fibrosis.
Insights
Sphingosine kinase 1 (SPHK1) drives thrombus fibrosis by promoting M2 macrophage polarization. Inhibiting SPHK1 with PF543 reduces fibrosis and M2 macrophage polarization, offering a potential therapeutic target for chronic thromboembolic pulmonary hypertension (CTEPH).
Area of Science:
- Vascular biology
- Immunology
- Fibrosis research
Background:
- Venous thrombus fibrosis is a key factor in post-thrombotic syndrome (PTS) and chronic thromboembolic pulmonary hypertension (CTEPH).
- M2 macrophages contribute to fibrosis by secreting transforming growth factor-beta 1 (TGF-β1).
- The role of sphingosine kinase 1 (SPHK1) in regulating M2 macrophage polarization and thrombus fibrosis requires investigation.
Purpose of the Study:
- To investigate whether SPHK1 promotes thrombus fibrosis by regulating M2 macrophage polarization.
- To evaluate the therapeutic potential of targeting SPHK1 in thrombus-associated fibrosis.
Main Methods:
- Histological staining and immunofluorescence (IF) on human thrombus tissues.
- Single-cell RNA sequencing (scRNA-seq) to analyze immune cell heterogeneity and SPHK1 expression.
- In vivo rat model of thrombus with SPHK1 inhibitor (PF543) treatment.
- In vitro studies using bone marrow-derived macrophages (BMDMs) and co-culture with fibroblasts.
Main Results:
- Increased extracellular matrix (ECM) deposition and macrophage infiltration in CTEPH thrombi.
- SPHK1 is highly expressed in M2 macrophage subsets and correlates with TGF-β1 secretion.
- PF543 treatment reduced collagen deposition, TGF-β1 expression, and M2 macrophage polarization in vivo.
- SPHK1 inhibition suppressed pro-fibrotic macrophage markers and M2-mediated fibroblast activation in vitro.
Conclusions:
- SPHK1 promotes M2 macrophage polarization and drives TGF-β1-dependent thrombus fibrosis, contributing to CTEPH progression.
- Pharmacological inhibition of SPHK1 effectively attenuates fibrotic remodeling and M2 macrophage polarization.
- SPHK1 represents a promising therapeutic target for treating chronic thrombus-associated fibrosis.
More Related Videos
11:38Visualization and Quantification of TGFβ/BMP/SMAD Signaling under Different Fluid Shear Stress Conditions using Proximity-Ligation-Assay
Published on: September 14, 2021
10:43Polarization of M1 and M2 Human Monocyte-Derived Cells and Analysis with Flow Cytometry upon Mycobacterium tuberculosis Infection
Published on: September 18, 2020
Related Concept Videos
TGF - β Signaling Pathway
Regulation of Angiogenesis and Blood Supply
Intracellular Signaling Affects Focal Adhesions
Some...
Clot Retraction and Fibrinolysis